An implantable continuous glucose monitor was shown to be safe and accurate in patients with type 1 and 2 diabetes, according to a study published in Diabetes Technology & Therapeutics.

Patients with diabetes depend on glucose monitors to provide information on their blood glucose levels, but carrying around these devices can be troublesome. In response, researchers, led by Lynne Kelley, MD, of Senseonics, tested the implantable continuous glucose monitor developed by Eversense in its ability to provide glucose values within the range of reference values.

"Continuous glucose monitoring is becoming standard of care especially for insulin-requiring patients with diabetes. Eversense, if approved by the FDA, will become the first implantable CGM system for use lasting at least three months," said Satish Garg, MD, editor-in-chief of Diabetes Technology & Therapeutics.

Developed by Eversense, the implant was provided to 90 participants in the PRECISE II study. Glucose values were collected over a 90-day period and compared to reference values. Results showed the implants were over 93 percent within the acceptable range of reference values.

“The results from this study demonstrate that the use of a long-term, 90-day, implantable continuous glucose sensor is accurate and safe with high rates of adherence to use,” wrote first author Mark Christiansen, MD, Leslie Klaff, MD, and colleagues. “Additional clinical studies will be required to evaluate the accuracy and usability of the Eversense CGM system among pediatrics, with reduced calibration frequency, and for extended durations through 180 days.”